HCPCS Level II
Q5111
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
Codes near Q5111
These sit next to Q5111 in the CMS Level II file. All Q codes
- Q5106Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Q5110Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5112Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg
- Q5113Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
- Q5114Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
- Q5115Injection, rituximab-abbs, biosimilar, (truxima), 10 mg
- Q5116Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 69448-0025-63 | Udenyca | Accord BioPharma, Inc | 12 |
| 69448-0026-63 | Udenyca | Accord BioPharma, Inc | 12 |
| 69448-0027-63 | Udenyca Onbody | Accord BioPharma, Inc | 12 |
| 70114-0101-01 | Udenyca | Coherus BioSciences, Inc. | 12 |
| 70114-0120-01 | Udenyca | Coherus BioSciences, Inc. | 12 |
| 70114-0130-01 | Udenyca | Coherus BioSciences, Inc. | 12 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.